EISAI CO

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public

Established: 1941-12-06

Employees: 11K

Market Cap: $12B

Website: http://www.eisai.co.jp

Clinical Trials

Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study

Phase 4

Completed

Conditions: COPD

Interventions: Drug: Lysozyme hydrochloride
Drug: Placebo

First Posted Date: 2012-07-20

Last Posted Date: 2015-10-21

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 408

Registration Number: NCT01645800

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Phase 3

Completed

Conditions: Partial-onset Seizures

Interventions: Drug: Placebo
Drug: Perampanel

First Posted Date: 2012-06-13

Last Posted Date: 2021-07-29

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 940

Registration Number: NCT01618695

Locations: 🇹🇭
Facility #3, Tha Muang, Thailand
🇰🇷
Facility #6, Seoul, Korea, Republic of
🇹🇭
Facility #1, Tha Muang, Thailand

and more 8 locations

Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Type Dementia

Interventions: Drug: E2020

First Posted Date: 2012-02-27

Last Posted Date: 2023-06-18

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 351

Registration Number: NCT01539031

A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males

Phase 1

Completed

Conditions: Healthy Adult

Interventions: Drug: Donepezil Hydrochloride

First Posted Date: 2012-01-10

Last Posted Date: 2012-06-27

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT01506752

A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males

Phase 1

Completed

Conditions: Healthy Adult

Interventions: Drug: Donepezil Hydrochloride

First Posted Date: 2012-01-10

Last Posted Date: 2012-01-10

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT01506739

Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

Completed

Conditions: Inoperable or Recurrent Breast Cancer

Interventions: Drug: Eribulin Mesylate

First Posted Date: 2011-11-02

Last Posted Date: 2023-07-24

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 963

Registration Number: NCT01463891

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Phase 2

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Drug: eribulin mesylate

First Posted Date: 2011-10-24

Last Posted Date: 2016-03-28

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 52

Registration Number: NCT01458249

E2022 Patch Formulation Multiple Dose Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: E2022
Drug: Placebo

First Posted Date: 2011-10-12

Last Posted Date: 2012-06-01

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT01450839

A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: E7389

First Posted Date: 2011-09-13

Last Posted Date: 2016-10-07

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT01432886

A Phase I Study of E7050 in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor
Gastric Cancer

Interventions: Drug: E7050

First Posted Date: 2011-09-02

Last Posted Date: 2014-02-14

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 18

Registration Number: NCT01428141

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy